Oslo, 27 May 2025: Zelluna ASA (the "Company") refers to the announcement on 24 May 2025 regarding a resolution by the Company's Board of Directors to issue 227,096 new shares in the Company against set-off of an option exercise fee. The share capital increase related to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises, and the Company's new registered share capital is NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1. Fo ...

Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's Annual General Meeting held on 29 April 2025 to grant the Company's Board of Directors an authorisation to issue new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The Company's Board of Directors has today resolved to issue 227,096 new shares in the Company to Inven2 against set-off of such amount of EUR 500,000. After the ...

文章核心观点 - 癌症治疗公司Zelluna公布2025年第一季度业绩，介绍业务进展、财务情况及公司使命 [1][5][6] 公司业务进展 - 2025年3月3日完成与Ultimovacs ASA业务合并及私募配售，获5.17亿挪威克朗收益 [5] - 2025年4月22日成功开发、扩大并自动化TCR - NK细胞疗法专有制造工艺，适用于公司管线产品，单批次可生产数百剂 [5] - 公司使命是为全球癌症患者提供安全、经济的变革性治疗，通过开发“现货型”TCR - NK细胞疗法实现，领先项目是针对MAGE - A4的“现货型”TCR - NK疗法 [6] 公司财务情况 - 2025年第一季度总运营费用2.22亿挪威克朗，运营净负现金流3.6亿挪威克朗 [5] - 2025年第一季度股权发行收益5.17亿挪威克朗，业务合并获得净现金9.23亿挪威克朗，现金及现金等价物净增加10.8亿挪威克朗 [5] - 截至2025年3月31日，现金及现金等价物达13.53亿挪威克朗 [5] 公司股权变动 - 2025年3月31日进行反向股票拆分，10股合为1股，公司流通股数量变为20,227,066股，每股面值1挪威克朗，为使总股数能被10整除，增发7股 [5] 信息披露安排 - 2025年5月8日07:00（CET）发布季度报告和演示文稿，同日09:00（CET）举行电话会议和网络直播，可提交问题，直播将存档 [1][4]